Discoidin domain receptor 1 as a promising biomarker for high-grade gliomas

dc.authorid0000-0003-0260-1988
dc.contributor.authorErdem, Dilek
dc.contributor.authorGünaldi, Meral
dc.contributor.authorKaraman, İrem
dc.contributor.authorAdilay, Utku
dc.contributor.authorYılmaz, İlhan Ümit
dc.contributor.authorEseoğlu, Metehan
dc.contributor.authorAvcıkurt, Ayla
dc.contributor.authorIşıksaçan, Nilgün
dc.contributor.authorErdoğan, Uzay
dc.contributor.authorGünaldı, Ömür
dc.date.accessioned2023-05-29T10:00:23Z
dc.date.available2023-05-29T10:00:23Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Beyin ve Sinir Cerrahisi Ana Bilim Dalı
dc.description.abstractBackground: Two fundamental challenges in the current therapeutic approach for central nervous system tumors are the tumor heterogeneity and the absence of specific treatments and biomarkers that selectively target the tumor tissue. Therefore, we aimed to investigate the potential relationship between discoidin domain receptor 1 (DDR1) expression and the prognosis and characteristics of glioma patients. Materials and Methods: Tissue and serum samples from 34 brain tumor patients were evaluated for DDR1 messenger ribonucleic acid levels in comparison to 10 samples from the control group, and Kaplan-Meier survival analysis has performed. Results: DDR1 expression was observed in both tissue and serum samples of the patient and control groups. DDR1 expression levels in tissue and serum samples from patients were higher in comparison to the control group, although not statistically significant (P > 0.05). A significant correlation between tumor size and DDR1 serum measurements at the level of 0.370 was reported (r = 0.370; P = 0.034). The levels of DDR1 in serum showed a positive correlation with the increasing size of tumor. The results of the 5-year survival analysis depending on the DDR1 tissue levels showed a significantly higher survival rate (P = 0.041) for patients who have DDR1 tissue levels above cutoff value. Conclusions: DDR1 expression was significantly higher among brain tumor tissues and serum samples and its levels showed a positive correlation with the increased size of tumor. This study can be a starting point, since it investigated and indicated, for the first time, that DDR1 can be a novel therapeutic and prognostic target for aggressive high-grade gliomas.
dc.identifier.citationErdem, D., Günaldi, M., Karaman, İ., Adilay, U., Yılmaz, İ. Ü., Eseoğlu, M. ... Günaldı, Ö. (2023). Discoidin domain receptor 1 as a promising biomarker for high-grade gliomas. Journal of Cancer Research and Therapeutics, 19(8), S285-S293. https://doi.org/10.4103/jcrt.jcrt_708_21
dc.identifier.doi10.4103/jcrt.jcrt_708_21
dc.identifier.endpageS293
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue8
dc.identifier.pmid37147958
dc.identifier.scopus2-s2.0-85159085382
dc.identifier.scopusqualityQ3
dc.identifier.startpageS285
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_708_21
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10987
dc.identifier.volume19
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorEseoğlu, Metehan
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectBiomarker
dc.subjectBrain Tumors
dc.subjectDiscoidin Domain Receptor
dc.subjectHigh-Grade Gliomas
dc.titleDiscoidin domain receptor 1 as a promising biomarker for high-grade gliomas
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Eseoglu-Metehan-2023.pdf
Boyut:
2.93 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: